Assignee
CYMABAY THERAPEUTICS INC
US·35 granted patents·19 pending applications·140 citations·filing 2012–2025
Top patents by PatentIndex Score
54 records- 0196US9616039B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2016·Granted Apr 11, 2017·31 cites·12 claims
- 0296US9381181B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2015·Granted Jul 5, 2016·38 cites·6 claims
- 0394US9486428B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2015·Granted Nov 8, 2016·14 cites·6 claims
- 0492US10512622B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·4 cites·10 claims
- 0591US10188620B2Treatment for NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·7 cites·19 claims
- 0691US9962346B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2017·Granted May 8, 2018·8 cites·13 claims
- 0790US9808436B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2016·Granted Nov 7, 2017·6 cites·9 claims
- 0890US9060987B2Methods for treating gout flaresCYMABAY THERAPEUTICS INC·Filed 2012·Granted Jun 23, 2015·5 cites·16 claims
- 0989US10272058B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2017·Granted Apr 30, 2019·5 cites·16 claims
- 1088US9439891B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2015·Granted Sep 13, 2016·3 cites·16 claims
- 1188US9433612B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2015·Granted Sep 6, 2016·3 cites·23 claims
- 1287US10813895B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2019·Granted Oct 27, 2020·1 cites·16 claims
- 1386US10828273B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·1 cites·9 claims
- 1486US10722483B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2019·Granted Jul 28, 2020·1 cites·19 claims
- 1586US10342770B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2018·Granted Jul 9, 2019·3 cites·19 claims
- 1685US10813896B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2019·Granted Oct 27, 2020·1 cites·10 claims
- 1785US8993797B2Crystalline solid and amorphous forms of (−)-halofenate and methods related theretoCYMABAY THERAPEUTICS INC·Filed 2013·Granted Mar 31, 2015·2 cites·8 claims
- 1882US10220011B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·2 cites·9 claims
- 1979US10478411B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2019·Granted Nov 19, 2019·1 cites·16 claims
- 2078US9801860B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2015·Granted Oct 31, 2017·1 cites·20 claims
- 2178US9737537B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCYMABAY THERAPEUTICS INC·Filed 2016·Granted Aug 22, 2017·1 cites·2 claims
- 2277US11596614B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2021·Granted Mar 7, 2023·0 cites·16 claims
- 2375US11000494B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Granted May 11, 2021·0 cites·16 claims
- 2475US9233914B2Crystalline solid and amorphous forms of (−)-halofenate and methods related theretoCYMABAY THERAPEUTICS INC·Filed 2015·Granted Jan 12, 2016·1 cites·6 claims
- 2574US11406611B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Granted Aug 9, 2022·0 cites·9 claims
- 2673US11179359B2Treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2020·Granted Nov 23, 2021·0 cites·19 claims
- 2772US11224580B2Treatment of intrahepatic cholestatic diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Granted Jan 18, 2022·0 cites·12 claims
- 2871US10292983B2Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditionsCYMABAY THERAPEUTICS INC·Filed 2017·Granted May 21, 2019·1 cites·22 claims
- 2969US11007162B2Methods of reducing small, dense LDL particlesCYMABAY THERAPEUTICS INC·Filed 2018·Granted May 18, 2021·0 cites·10 claims
- 3069US10137112B2Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentCYMABAY THERAPEUTICS INC·Filed 2017·Granted Nov 27, 2018·0 cites·9 claims
- 3169US2026055055A1Process for making seladelparCYMABAY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3267US9925189B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCYMABAY THERAPEUTICS INC·Filed 2017·Granted Mar 27, 2018·0 cites·2 claims
- 3364US9845285B2Crystalline solid and amorphous forms of (−)-halofenate and methods related theretoCYMABAY THERAPEUTICS INC·Filed 2015·Granted Dec 19, 2017·0 cites·20 claims
- 3464US8921350B2Heterocyclic receptor agonists for the treatment of diabetes and metabolic disordersCYMABAY THERAPEUTICS INC·Filed 2013·Granted Dec 30, 2014·0 cites·4 claims
- 3563US2024252499A1Treatment of uremic pruritusCYMABAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3663US2024252500A1Treatment of chronic pruritic dermatosesCYMABAY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3762US2021283078A1Treatment of cholestatic pruritusCYMABAY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3861US9150567B2Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine saltsCYMABAY THERAPEUTICS INC·Filed 2014·Granted Oct 6, 2015·0 cites·5 claims
- 3960US2019105291A1Treatment of cholestatic pruritusCYMABAY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4059US2018055803A1Methods for Treating Gout FlaresCYMABAY THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4159US2026060948A1Methods for treating liver diseaseCYMABAY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4258US2022241228A1Treatment of cholangiopathiesCYMABAY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4356US2021355065A1CB-0406 tromethamine saltCYMABAY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4456US2021355066A1CB-0406 choline saltCYMABAY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4553US2020155650A1Combination treatment of NAFLD and NASHCYMABAY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4653US2020155487A1Treatment of obesity and its complicationsCYMABAY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4750US10098843B2Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidineCYMABAY THERAPEUTICS INC·Filed 2016·Granted Oct 16, 2018·0 cites·15 claims
- 4849US2021145775A1Treatment of intestinal barrier dysfunction and associated diseasesCYMABAY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4949US2021145774A1Treatment of alcoholic liver diseaseCYMABAY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5047US2016324811A1Methods of reducing small, dense ldl particlesCYMABAY THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →